Pulmonary embolism cost-effectiveness of therapy

Editor(s)-In-Chief: The APEX Trial Investigators, C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Rim Halaby, M.D. [2]

Overview

When indicated, early discharge and outpatient treatment for pulmonary embolism is more cost effective than inpatient treatment.^[1] The inpatient treatment with low molecular weight heparin has been reported to be more cost effective than that with unfractionated heparin.^[1]

References

↑ ^1.0 ^1.1 Aujesky D, Smith KJ, Cornuz J, Roberts MS (2005). “Cost-effectiveness of low-molecular-weight heparin for treatment of pulmonary embolism”. Chest. 128 (3): 1601–10. doi:10.1378/chest.128.3.1601. PMID 16162764.

Template:WH Template:WS

[pmid16162764-1] 1.0 ^1.1 Aujesky D, Smith KJ, Cornuz J, Roberts MS (2005). “Cost-effectiveness of low-molecular-weight heparin for treatment of pulmonary embolism”. Chest. 128 (3): 1601–10. doi:10.1378/chest.128.3.1601. PMID 16162764.

[1]